ICH Intercable Ich Inc.

Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the
development of products that prevent and remove microbial biofilms, is pleased
to announce that the creation of the Master Cell Bank for manufacturing
DispersinB(TM) has successfully been completed. The Master Cell Bank provides a
pure cell culture for manufacturing clinical grade DispersinB(TM) by
fermentation in a cGMP facility.


"This is a key step in the manufacturing process of clinical grade
DispersinB(TM)", stated Gord Froehlich, President and CEO for Kane Biotech. "We
are very pleased with the progress BioVectra has made and we now look forward to
the next step of manufacturing the antimicrobial wound gel using clinical grade
DispersinB(TM)."


"The successful creation and quality release of the DispersinB(TM) Master Cell
Bank represents a significant milestone in the creation of a commercial process
for the DispersinB(TM) wound gel", stated Scott Doncaster, Director of
Manufacturing for BioVectra. "The DispersinB(TM) Master Cell Bank was designed
to be 100% compliant with the current International Conference on Harmonization
("ICH") quality guidelines for expression constructs of therapeutic proteins
(ICH Q5B). As the DispersinB(TM) wound gel progresses through the developmental
phases, this compliance standard will allow for the acceptance of the
DispersinB(TM) manufacturing process by worldwide regulating agencies."


DispersinB(TM) is a novel antibiofilm enzyme capable of both inhibiting and
dispersing bacterial biofilms. Kane Biotech has received a patent from the U.S.
Patent and Trademark Office for DispersinB(TM) and has been awarded a $405,000
contribution from the National Research Council-Industrial Research Assistance
Program (NRC-IRAP) to further develop this technology. Kane Biotech is presently
using DispersinB(TM) alone, and in combination with other antimicrobial agents,
to develop a wound care therapy and a proprietary medical device coating.


About BioVectra Inc.

BioVectra Inc. is a growing Canadian biopharmaceutical company focused on
contract manufacturing and product development of active pharmaceutical
ingredients, pharmaceutical intermediates and bioreagents. Located in Prince
Edward Island, Canada, BioVectra currently holds 8 Drug Master File filings and
is an active supplier to most of the major pharmaceutical, biotechnology, and
diagnostic companies in North America and Europe. BioVectra is well positioned
to provide full cGMP development and production expertise to the Canadian and
World Biotech markets.


About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development of products
to prevent and remove biofilms. Biofilms are a major cause of a number of
serious medical problems including chronic infections and medical device related
infections. They develop on surfaces such as catheters, prosthetic implants,
teeth, lungs and the urogenital tract. Biofilms are pervasive, costly to deal
with and are involved in approximately 80% of all human bacterial infections.
The healing of chronic wounds alone costs the Unites States health care system
$20 Billion per year.




Kane Biotech is currently developing two lead technology platforms:

- DispersinB(TM), a novel antibiofilm enzyme that inhibits as well as
  disperses microbial biofilms, with applications in wound care, medical
  devices, oral care and animal healthcare. Kane is currently developing
  a DispersinB(TM) based antibiofilm/antimicrobial wound gel for healing
  chronic wounds.

- PS/CHX, a broad-spectrum antimicrobial/antibiofilm composition comprising
  FDA-approved protamine sulfate and chlorhexidine, with applications in
  anti-infective medical device coatings, animal care and dairy and food
  processing industries. This technology has been licensed to Harland
  Medical Systems to develop antimicrobial urinary and venous access
  catheters.



Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking
information within the meaning of applicable Canadian provincial securities
legislation (collectively, "forward-looking statements"). These forward-looking
statements relate to, among other things, our objectives, goals, targets,
strategies, intentions, plans, beliefs, estimates and outlook, including,
without limitation, our anticipated future operating results, and can, in some
cases, be identified by the use of words such as "believe," "anticipate,"
"expect," "intend," "plan," "will," "may" and other similar expressions. In
addition, any statements that refer to expectations, projections or other
characterizations of future events or circumstances are forward-looking
statements.


These statements reflect management's current beliefs and are based on
information currently available to management. Certain material factors or
assumptions are applied in making forward-looking statements, and actual results
may differ materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ materially from
these expectations include, among other things: Kane's early stage of
development, lack of product revenues and history of operating losses,
uncertainties related to clinical trials and product development, rapid
technological change, uncertainties related to forecasts, competition, potential
product liability, additional financing requirements and access to capital,
unproven markets, supply of raw materials, income tax matters, management of
growth, partnerships for development and commercialization of technology,
effects of insurers' willingness to pay for products, system failures,
dependence on key personnel, foreign currency risk, risks related to regulatory
matters and risks related to intellectual property and other risks detailed from
time to time in Kane's filings with Canadian securities regulatory authorities,
as well as Kane's ability to anticipate and manage the risks associated with the
foregoing. Kane cautions that the foregoing list of important factors that may
affect future results is not exhaustive. When relying on Kane's forward-looking
statements to make decisions with respect to Kane, investors and others should
carefully consider the foregoing factors and other uncertainties and potential
events.


These risks and uncertainties should be considered carefully and prospective
investors should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in this press release are
based upon what management believes to be reasonable assumptions, Kane cannot
provide assurance that actual results will be consistent with these
forward-looking statements. Kane undertakes no obligation to update or revise
any forward-looking statement.

Intercable Ich Inc. (TSXV:ICH)
Historical Stock Chart
From Jun 2024 to Jul 2024

Intercable Ich Inc. (TSXV:ICH)
Historical Stock Chart
From Jul 2023 to Jul 2024